{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-014127","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2022-09-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.560877+00:00","generated_at":"2026-06-23T17:07:38.301015+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Protalix BioTherapeutics enters fill/finish deal with Chiesi for PRX-102 launch","bullets":["Agreement with Chiesi for commercial fill/finish services for PRX-102 (Fabry disease candidate).","Protalix to supply drug substance; Chiesi will provide fill/finish services for global launch.","Term through Dec 31, 2025, renewable for 7 years by mutual agreement.","Letter Agreement modifies License Agreements to establish Chiesi as supplier and potential alternate source.","Agreement supports anticipated launch; no financial terms disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-014127","json":"https://secwatch.observer/filing/0001558370-22-014127.json","markdown":"https://secwatch.observer/filing/0001558370-22-014127.md","text":"https://secwatch.observer/filing/0001558370-22-014127.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000155837022014127/0001558370-22-014127-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000155837022014127/plx-20220829x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T17:07:38.301015+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}